Table 2 |
|||||
|
Rates of all severe infections, according to agent, number of courses, and main autoimmune diseases |
|||||
|
Patients |
Person-years |
Number of infections |
Rate of infections/ 1,000 person-years |
95% Confidence interval |
|
|
|
|||||
|
TOTAL |
344 |
495 |
45 |
90.90 |
66.31 to 121.64 |
|
RITUXIMAB |
|||||
|
- Total |
264 |
328.83 |
37 |
112.52 |
79.20 to 155.10 |
|
- First course |
211 |
252.17 |
30 |
119.00 |
88.03 to 169.80 |
|
- Second course |
38 |
54.58 |
2 |
36.64 |
4.44 to 132.37 |
|
- Third or subsequent courses |
15 |
22.08 |
5 |
226.40 |
73.50 to 528.50 |
|
ANTI-TNF AGENTS |
|||||
|
- Total |
77 |
147.58 |
8 |
54.21 |
23.40 to 106.81 |
|
- Infliximab |
37 |
52.00 |
4 |
76.92 |
20.96 to 196.95 |
|
- Adalimumab |
19 |
29.91 |
2 |
66.85 |
8.10 to 241.55 |
|
- Etanercept |
21 |
65.67 |
2 |
30.46 |
3.69 to 110.02 |
|
DISEASES |
|||||
|
- SLE |
140 |
175.42 |
11 |
62.71 |
31.30 to 112.20 |
|
- Systemic vasculitis |
50 |
74.75 |
11 |
147.16 |
73.50 to 263.30 |
|
- Inflammatory myopathies |
38 |
60.42 |
7 |
115.86 |
46.60 to 238.70 |
|
- Behçet disease |
31 |
61.25 |
2 |
32.65 |
3.95 to 117.95 |
|
- Sjögren syndrome |
23 |
31.92 |
3 |
93.98 |
19.38 to 274.66 |
|
DISEASE/AGENT |
|||||
|
- Behçet disease/IFX |
20 |
36.50 |
1 |
27.39 |
0.68 to 152.65 |
|
- Cryoglobulinemia/RTX |
15 |
14.17 |
4 |
282.30 |
76.90 to 722.80 |
|
- Wegener granulomatosis/RTX |
18 |
29.00 |
4 |
137.90 |
37.60 to 353.20 |
|
- SLE/RTX |
139 |
171.08 |
11 |
64.30 |
32.09 to 115.04 |
|
- Inflammatory myopathies/RTX |
27 |
32.17 |
2 |
62.18 |
7.53 to 224.61 |
|
- Sjögren syndrome/RTX |
21 |
24.00 |
3 |
125.00 |
25.80 to 365.30 |
|
INDICATION |
|||||
|
- Refractory disease |
296 |
421.17 |
38 |
90.22 |
63.85 to 123.84 |
|
- Life-threatening situation |
48 |
73.83 |
7 |
94.81 |
38.12 to 195.35 |
|
|
|||||
|
IFX, infliximab; RTX, rituximab; SLE, systemic lupus erythematosus. |
|||||
|
Díaz-Lagares et al. Arthritis Research & Therapy 2011 13:R112 doi:10.1186/ar3397 |
|||||
